Evidence map›Paper›PMID 30788072›Full record

ArticleJournal of community hospital internal medicine perspectives2019

A case of Loeffler's endocarditis after initiation of adalimumab.

Nooreen Hussain, Preeti Patel, Jonathan Yin, Rachael Davis, Ossama Ikladios

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of community hospital internal medicine perspectives, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nooreen HussainDepartment of Internal Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA.ORCID 0000-0002-6439-3865
Preeti PatelDepartment of Critical Care/Pulmonary Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA.
Jonathan YinDepartment of Internal Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA.
Rachael DavisDepartment of Critical Care/Pulmonary Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA.
Ossama IkladiosDepartment of Critical Care/Pulmonary Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA.
University of Illinois Urbana-Champaign · USIllinois College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor necrosis factor antagonists (anti-TNF) are increasingly prescribed as maintenance therapy for a variety of autoimmune conditions. Therefore, frequent monitoring and awareness of side effects are of the utmost importance. Adalimumab is known to cause peripheral eosinophilia, but there are few reports of more severe adverse events. Loeffler's endocarditis is a rare and fatal disease characterized by eosinophilic infiltration of the endomyocardium leading to fibrosis and restrictive cardiomyopathy. Herein we describe a 72 year old female on adalimumab therapy for two years for rheumatoid arthritis presenting with Loeffler's endocarditis. This case represents a rare case of Loeffler's endocarditis diagnosed rapidly and without myocardial biopsy. Early intervention is crucial in the prevention of permanent fibrosis and mortality in Loeffler's endocarditis. This case demonstrates the need for close monitoring and early recognition in patients on anti-TNF therapy.

Indexed as

Adalimumabhypereosinophilic syndromeLoeffler’s endocarditisperipheral eosinopheliatumor necrosis factor

Identifiers

PMID30788072
PMCPMC6374942
OpenAlexW2912867455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.